Optigenex Inc. Reports Positive Results From a Double-Blind, Placebo Controlled Study of Onnit Labs Flagship Product, AlphaBr...
25 Februar 2014 - 6:11PM
Marketwired
Optigenex Inc. Reports Positive Results From a Double-Blind,
Placebo Controlled Study of Onnit Labs Flagship Product,
AlphaBrain(TM) With ac-11(R)
Pilot Study Sponsored by Onnit and Conducted by the Boston
Center for Memory, Demonstrates Significant Statistical
Improvements in Key Neurogenic Markers, Including Memory, Problem
Solving and Reasoning
HOBOKEN, NJ--(Marketwired - Feb 25, 2014) - Optigenex Inc. (OTC
Pink: OPGX) announced today the results of a pilot study entitled
"A Proof of Concept Study for a Randomized Double-Blind, Placebo
Controlled, Parallel Group, Efficacy Study of AlphaBrain™
administered orally," conducted by the Boston Center for
Memory. The purpose of the study was to test the efficacy of
AlphaBrain™ with ac-11® as an enhancer of cognitive ability,
including memory, attention, problem solving and reasoning.
Developed by Optigenex, AC-11® is a patented, all natural rain
forest botanical extract shown to help the body's natural ability
to repair damaged DNA. The Onnit-sponsored study, which
utilized a methodology and study design similar to that
applied in new drug evaluations, but not often used in research to
evaluate dietary supplements, demonstrated statistically
significant improvements in areas related to memory and "executive
function" (e.g., reasoning and problem solving) among the test
subject volunteers taking AlphaBrain™ with ac-11®.
Anthony Worth, Managing Director of Optigenex, said, "We are
delighted by the findings. Prior research had shown a marked
promise for ac-11® in the areas of neuro-protection and
neuro-enhancement. But now, in a carefully planned and well
focused study, Onnit and the Boston Center for Memory have teamed
up to generate reliable data points showing the unique way in which
AlphaBrain™ with ac-11® works to enhance cognitive
function. The results from the study are impressive enough,
moreover, to confirm our long standing belief that ac-11® works
synergistically with the other beneficial neuro-nutrients found in
the AlphaBrain™ formula to further enhance the benefits we
previously have seen with ac-11® alone."
Discussing the company's relationship with Onnit, Mr. Worth
added, "Since early 2010, Onnit's track record of growth in sales
and industry influence, from essentially nil as 'just
another on-line startup' to extraordinary as a rising leader in
cutting edge health care products, has been, from our perspective,
nothing short of stunning. That growth has come in large part
from Onnit's many satisfied customers, young and old, who almost
literally form a 'community' centered around Onnit's progressive,
and yet quite sound, wellness philosophy. The fact that
Onnit's management is focused on new research and not simply
content to rest on its customer-driven success demonstrates its
commitment to a solid foundation for future growth. And in
that regard, while we are very pleased with the work that has been
done at the Boston Center, we look forward to seeing the results
from a larger study currently underway utilizing new benchmarks
that both we and Onnit believe will provide deeper insights into
the mechanisms of action in play when AlphaBRAIN™ with ac-11® is
taken by healthy individuals."
Aubrey Marcus, CEO of Onnit Labs, LLC, said, "AC-11® is the
epitome of the type of ingredient we look for in creating our
formulas. Sourced from an Earth-grown nutrient (Uncaria
tomentosa) and elevated to a highly potent and unique compound
through natural, non-chemical methods, ac-11® is the perfect blend
of nature and science. As a key ingredient in the proprietary
AlphaBRAIN™ formula, we believe ac-11® plays a fundamental role in
enhancing the efficacy of the other ingredients, while also helping
to provide a greater sense of mental vitality."
To view the results of the study, please visit:
https://www.onnit.com/clinical-studies/alpha-brain-clinical-trial/
About Optigenex Inc.:
Optigenex is a formulator, distributor and provider of
proprietary next generation, dietary supplements, skin care
products and bulk ingredient featuring ac-11® as its core platform
technology. AC-11® (formerly known as C-MED-100®) is a
patented, bioactive and water soluble rain forest ingredient
derived from the medicinal herb Uncaria
tomentosa. For more information about Optigenex, please
visit: www.optigenex.com
About Onnit Labs LLC:
Onnit is an Austin, TX based health and wellness company focused
on encouraging peak human performance through a combination of
unique products and actionable information. With strategies
from leading professional athletes and medical practitioners, Onnit
is committed to creating naturally derived nutritional supplements
and functional foods based upon the latest ingredient science and
dietary research. For more information visit: www.Onnit.com or
contact Orlando@Onnit.com.
*The statements made in this press release have not been
evaluated by the Food and Drug Administration (FDA). The products
mentioned herein are not intended to treat, diagnose, cure or
prevent any disease.
This Press Release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
with respect to our financial condition, results of operations and
business. These forward-looking statements can be identified by the
use of terms such as "believe," "expects," "plan," "intend," "may,"
"will," "should," "can," or "anticipates," or the negative thereof,
or variations thereon, or comparable terminology, or by discussions
of strategy. These statements involve known and unknown risks,
uncertainties and other factors that may cause industry trends or
our actual results to be materially different from any future
results expressed or implied by these statements. Important factors
that may cause our results to differ from these forward-looking
statements include, but are not limited to: (i) changes in or new
government regulations or increased enforcement of the same, (ii)
increased costs, including from increased raw material or energy
prices, (iii) changes in general worldwide economic or political
conditions, (iv) adverse publicity or negative consumer perception
regarding nutritional supplements, (v) issues with obtaining raw
materials of adequate quality or quantity, (vi) litigation and
claims, including product liability, intellectual property and
other types, (vii) disruptions from or following acquisitions
including the loss of customers, (viii) increased competition, (ix)
slow or negative growth in the nutritional supplement industry or
the healthy foods channel, (x) the loss of key personnel or the
inability to manage our operations efficiently, (xi) problems with
information management systems, manufacturing efficiencies and
operations, (xii) insurance coverage issues, (xiii) the volatility
of the stock market generally and of our stock specifically, and
(xiv) interruption of business or negative impact on sales and
earnings due to acts of God, acts of war, terrorism, bio-terrorism,
civil unrest and other factors outside of our control.
Contact: Daniel Zwiren dzwiren@optigenex.com 201 653 5195
Optigenex (CE) (USOTC:OPGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Optigenex (CE) (USOTC:OPGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024